Business
AACR Presentation Update
AACR Presentation Update.
About this update from Physiomics Plc
[{"type":"text","content":"\n Physiomics PLC\n08 April 2008\n\n\n\n\n\n Physiomics plc\n The Magdalen Centre\n The Oxford Science Park\n Robert Robinson Avenue\n Oxford\n OX4 4GA\n UK\n\n Tel 01865 784980\n Fax 08701 671931\n\n08 April 2008\n\n\n\n Physiomics plc ('Physiomics' or 'the Company')\n\nPhysiomics to present on Cyclacel Pharmaceuticals collaboration on Aurora Kinase\n research program at the Annual Meeting of American Association of Cancer\n Research ('AACR')\n\nPhysiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is\npleased to announce that it will be participating in the 2008 AACR Annual\nMeeting, taking place in San Diego, on 12-16 April 2008. Dr Christophe\nChassagnole, Chief Operating Officer of Physiomics, will present the results of\na recent collaboration with Cyclacel pharmaceuticals Inc. (NASDAQ: CYCC, NASDAQ:\nCYCCP). It will be shown how Physiomics technologies have been used to support a\npre-clinical research program on a novel Aurora Kinase inhibitor CYC116 that has\nsince entered in a phase 1 clinical research program. The abstract ('Systems\nbiology analysis of a novel Aurora kinase inhibitor: CYC116', No 1645) will be\npublished in the 2008 Proceeding of the AACR and will be presented in the poster\nsession 'Cellular and Molecular Biology 16', scheduled for 8:00 am 12:00 pm on\n14 April.\n\n\nMore information about the conference may be found at www.aacr.org\n\n\nFor further information:\nPhysiomics plc +44 (0)1865 784980\nDr Christophe Chassagnole, COO\nE-mail: [email protected]\nGrant Thornton Corporate Finance +44 (0)20 7383 5100\nPhilip Secrett, Colin Aaronson\n\n\nAbout Physiomics plc\n\nPhysiomics plc (AIM:PYC) is a computational systems biology services company\napplying simulations of cell behaviour to drug development to reduce the high\nattrition rates of clinical trials. As 80-90 per cent of all clinical drug\ncandidates fail to reach the market, estimates1 show that an overall ten per\ncent improvement in success rates could reduce the cost of one drug's\ndevelopment by as much as $242 million, from the current estimate of around $800\nmillion.\n\nPhysiomics develops computational systems biology models to predict and\nunderstand cancer drug efficacy from pre-clinical research to clinical\ndevelopment. Physiomics has created detailed mathematical models incorporating\nmost importa...